Adam Gault Tyra Biosciences ( NASDAQ: TYRA ) has been upgraded to buy by BofA ahead of an expected data readout next week from a Phase 1/2 study of its FGFR3-inhibitor TYRA-300 for urothelial carcinoma and solid tumors. BofA said that while Johnson & Johnson’s (.
Back to Health Page
